Glutathione S-transferase Pi expression predicts response to adjuvant chemotherapy for stage C colon cancer: a matched historical control study

BMC Cancer

Research Article

Mark Molloy¹  Lucy Jankova²  Graham Robertson²  Maija Kohonen-Corish³  Betty P C Lin⁴  Charles Chan⁴  King L Tan⁵  Caroline L-S Fung⁵  Candice Clarke⁵  Owen F Dent⁶  Les Bokey⁶  Pierre H Chapuis⁶  Stephen J Clarke⁷ 

[1] Australian Proteome Analysis Facility and Department of Chemistry and Biomolecular Sciences, Macquarie University, 2109, Sydney, NSW, Australia;Cancer Pharmacology Unit, ANZAC Research Institute, Concord Hospital, The University of Sydney, 2139, Sydney, NSW, Australia;Cancer Research Program, Garvan Institute of Medical Research and St Vincent’s Clinical School, University of New South Wales, 2052, Sydney, NSW, Australia;Department of Anatomical Pathology, Concord Hospital and Discipline of Pathology, The University of Sydney, 2139, Sydney, NSW, Australia;Department of Anatomical Pathology, Concord Hospital, 2139, Sydney, NSW, Australia;Department of Colorectal Surgery, Concord Hospital and Discipline of Surgery, The University of Sydney, 2139, Sydney, NSW, Australia;Department of Medicine, Concord Hospital and Discipline of Medicine, The University of Sydney, 2139, Sydney, NSW, Australia;

关键词: Colon cancer;    GST Pi;    Adjuvant chemotherapy;    Survival;   

DOI  :  10.1186/1471-2407-12-196

 received in 2011-12-24, accepted in 2012-05-11,  发布年份 2012

来源: Springer

【 摘 要 】

BackgroundThis study examined the association between overall survival and Glutathione S-transferase Pi (GST Pi) expression and genetic polymorphism in stage C colon cancer patients after resection alone versus resection plus 5-fluourouracil-based adjuvant chemotherapy.MethodsPatients were drawn from a hospital registry of colorectal cancer resections. Those receiving chemotherapy after it was introduced in 1992 were compared with an age and sex matched control group from the preceding period. GST Pi expression was assessed by immunohistochemistry. Overall survival was analysed by the Kaplan-Meier method and Cox regression.ResultsFrom an initial 104 patients treated with chemotherapy and 104 matched controls, 26 were excluded because of non-informative immunohistochemistry, leaving 95 in the treated group and 87 controls. Survival did not differ significantly among patients with low GST Pi who did or did not receive chemotherapy and those with high GST Pi who received chemotherapy (lowest pair-wise p = 0.11) whereas patients with high GST Pi who did not receive chemotherapy experienced markedly poorer survival than any of the other three groups (all pair-wise p <0.01). This result was unaffected by GST Pi genotype.ConclusionStage C colon cancer patients with low GST Pi did not benefit from 5-fluourouracil-based adjuvant chemotherapy whereas those with high GST Pi did.

【 授权许可】

Unknown   
© Jankova et al.; licensee BioMed Central Ltd. 2012. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.